Current Market Access to Atopic Dermatitis Medications

The FDA in February accepted a New Drug Application under priority review for Incyte Corp.’s ruxolitinib cream for the treatment of atopic dermatitis. Meanwhile, there are currently more than 10 agents in Phase III trials for this indication. Among the medications that are on the market, Sanofi and Regeneron’s Dupixent (dupilumab) and Pfizer Inc.’s Eucrisa (crisaborole) are competing for preferred status after topical corticosteroids, topical calcineurin inhibitors and phototherapy. Most medications are covered under the pharmacy benefit, with the exception of Dupixent. More than half of payer pharmacy benefit formularies do not require step therapy or prior authorization for atopic dermatitis medications.

NOTE: Under the pharmacy benefit, the total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 170.0 million, 11.7 million, 47.8 million and 69.8 million, respectively. Under the medical benefit, the total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 168.4 million, 11.7 million, 49.5 million and 69.8 million, respectively.

SOURCE: Managed Markets Insight & Technology, LLC database as of May 2021.

© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

May 16

Balancing Technology, Human Touch Can Improve Therapy Access, Adherence

Read More
May 16

FDA Approves Second Gene Therapy, but Will Price Prove to Be Too High?

Read More
May 16

Walgreens Will Launch New Specialty Pharmacy With ‘Significant’ Cell and Gene Therapy Offering

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today